Abciximab readministration

James L. Orford, David Holmes

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

The IIb/IIIa receptor inhibitors have been shown to improve outcomes following percutaneous coronary intervention (PCI), particularly by decreasing periprocedural myocardial necrosis. Abciximab has been subject to multiple studies, demonstrating consistent improved early and late outcomes in multiple patient populations, including a mortality advantage in diabetics, but there has been concern about the possibility of anaphylaxis, thrombocytopenia, and reduced clinical efficacy with repeat administration of abciximab. Results of the ReoPro Readministration Registry, a prospective, phase IV, multicenter registry of 500 patients undergoing PCI who were treated with abciximab at least 7 days after a previous treatment with this same drug, support the contention that abciximab readministration is both safe and clinically efficacious and that there is no significant increase in the incidence of thrombocytopenia as compared with historical controls of trials of first abciximab administration. However, profound thrombocytopenia did occur with increased frequency as compared with historical controls, suggesting a shift from mild to profound thrombocytopenia with abciximab readministration.

Original languageEnglish (US)
Pages (from-to)67-70
Number of pages4
JournalReviews in Cardiovascular Medicine
Volume3
Issue number2
StatePublished - Jul 2 2002

Fingerprint

Thrombocytopenia
Percutaneous Coronary Intervention
Registries
Anaphylaxis
abciximab
Necrosis
Mortality
Incidence
Pharmaceutical Preparations
Population
Therapeutics

Keywords

  • Abciximab
  • IIb/IIIa receptor inhibitors
  • Percutaneous coronary intervention
  • Thrombocytopenia

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Abciximab readministration. / Orford, James L.; Holmes, David.

In: Reviews in Cardiovascular Medicine, Vol. 3, No. 2, 02.07.2002, p. 67-70.

Research output: Contribution to journalReview article

Orford, JL & Holmes, D 2002, 'Abciximab readministration', Reviews in Cardiovascular Medicine, vol. 3, no. 2, pp. 67-70.
Orford, James L. ; Holmes, David. / Abciximab readministration. In: Reviews in Cardiovascular Medicine. 2002 ; Vol. 3, No. 2. pp. 67-70.
@article{13848f1673f74925bcf8e23f245bd48a,
title = "Abciximab readministration",
abstract = "The IIb/IIIa receptor inhibitors have been shown to improve outcomes following percutaneous coronary intervention (PCI), particularly by decreasing periprocedural myocardial necrosis. Abciximab has been subject to multiple studies, demonstrating consistent improved early and late outcomes in multiple patient populations, including a mortality advantage in diabetics, but there has been concern about the possibility of anaphylaxis, thrombocytopenia, and reduced clinical efficacy with repeat administration of abciximab. Results of the ReoPro Readministration Registry, a prospective, phase IV, multicenter registry of 500 patients undergoing PCI who were treated with abciximab at least 7 days after a previous treatment with this same drug, support the contention that abciximab readministration is both safe and clinically efficacious and that there is no significant increase in the incidence of thrombocytopenia as compared with historical controls of trials of first abciximab administration. However, profound thrombocytopenia did occur with increased frequency as compared with historical controls, suggesting a shift from mild to profound thrombocytopenia with abciximab readministration.",
keywords = "Abciximab, IIb/IIIa receptor inhibitors, Percutaneous coronary intervention, Thrombocytopenia",
author = "Orford, {James L.} and David Holmes",
year = "2002",
month = "7",
day = "2",
language = "English (US)",
volume = "3",
pages = "67--70",
journal = "Reviews in Cardiovascular Medicine",
issn = "1530-6550",
publisher = "MedReviews LLC",
number = "2",

}

TY - JOUR

T1 - Abciximab readministration

AU - Orford, James L.

AU - Holmes, David

PY - 2002/7/2

Y1 - 2002/7/2

N2 - The IIb/IIIa receptor inhibitors have been shown to improve outcomes following percutaneous coronary intervention (PCI), particularly by decreasing periprocedural myocardial necrosis. Abciximab has been subject to multiple studies, demonstrating consistent improved early and late outcomes in multiple patient populations, including a mortality advantage in diabetics, but there has been concern about the possibility of anaphylaxis, thrombocytopenia, and reduced clinical efficacy with repeat administration of abciximab. Results of the ReoPro Readministration Registry, a prospective, phase IV, multicenter registry of 500 patients undergoing PCI who were treated with abciximab at least 7 days after a previous treatment with this same drug, support the contention that abciximab readministration is both safe and clinically efficacious and that there is no significant increase in the incidence of thrombocytopenia as compared with historical controls of trials of first abciximab administration. However, profound thrombocytopenia did occur with increased frequency as compared with historical controls, suggesting a shift from mild to profound thrombocytopenia with abciximab readministration.

AB - The IIb/IIIa receptor inhibitors have been shown to improve outcomes following percutaneous coronary intervention (PCI), particularly by decreasing periprocedural myocardial necrosis. Abciximab has been subject to multiple studies, demonstrating consistent improved early and late outcomes in multiple patient populations, including a mortality advantage in diabetics, but there has been concern about the possibility of anaphylaxis, thrombocytopenia, and reduced clinical efficacy with repeat administration of abciximab. Results of the ReoPro Readministration Registry, a prospective, phase IV, multicenter registry of 500 patients undergoing PCI who were treated with abciximab at least 7 days after a previous treatment with this same drug, support the contention that abciximab readministration is both safe and clinically efficacious and that there is no significant increase in the incidence of thrombocytopenia as compared with historical controls of trials of first abciximab administration. However, profound thrombocytopenia did occur with increased frequency as compared with historical controls, suggesting a shift from mild to profound thrombocytopenia with abciximab readministration.

KW - Abciximab

KW - IIb/IIIa receptor inhibitors

KW - Percutaneous coronary intervention

KW - Thrombocytopenia

UR - http://www.scopus.com/inward/record.url?scp=0035997865&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035997865&partnerID=8YFLogxK

M3 - Review article

C2 - 12447149

AN - SCOPUS:0035997865

VL - 3

SP - 67

EP - 70

JO - Reviews in Cardiovascular Medicine

JF - Reviews in Cardiovascular Medicine

SN - 1530-6550

IS - 2

ER -